PPCB · Propanc Biopharma, Inc. · Executive Compensation
$1.99
+0.07 (+3.65%)
At close · Nov 13
Return incl. dividend (before tax)
Going-concern doubt
— flagged Sep 25, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These matters raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-K filed Sep 25, 2026
Market Cap
$1.22M
Shares
633,112
Volume · Nov 12
21.9K
Avg daily vol (14 sessions)
35.67K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Carlo Campiciano | Board of Directors | Appointed | 2026-07-14 |
| Annie Van Broekhoven | Board of Directors | Retired | 2026-07-14 |
| Dr. Ralf Brandt | Board | Appointed | 2026-02-26 |
| Dr. Julian Kenyon | Board of Directors | Retired | 2026-02-26 |
| Annie VanBroekhoven | member of the Company's Board of Directors | Appointed | 2025-08-19 |
| Joseph Himy | member of the Company's Board of Directors | Appointed | 2025-08-19 |
| Jeannine Zimmerman | Chief Financial Officer | Appointed | 2025-08-13 |
Leadership
- James Nathanielsz CFO
- Jeannine Zimmerman CFO
- Annie VanBroekhoven Board Member
- Carlo Campiciano Board Member
- Dr. Ralf Brandt Board Member
- Josef Zelinger Board Member
- Joseph Himy Board Member